Kasugamycin (hydrochloride)
(Synonyms: 春雷霉素盐酸盐; Ksg hydrochloride) 目录号 : GC12556An aminoglycosidic antibiotic
Cas No.:19408-46-9
Sample solution is provided at 25 µL, 10mM.
Kasugamycin is an aminoglycosidic antibiotic.
Aminoglycoside, a medicinal and bacteriologic category of traditional Gram-negative antibacterial therapeutic agent, inhibits protein synthesis and contains as a portion of the molecule an amino-modified glycoside.
In vitro: Kasugamycin could inhibit protein synthesis by interacting with the 30S ribosomal subunit. The mechanism of inhibition of protein synthesis appeared to be different from that of other aminoglycosides, such as kanamycin, streptomycin, neomycin, gentamicin. The initiation complex formation on 30S ribosomes could be inhibited by kasugamycin but not by streptomycin, kanamycin or gentamicin, though the binding of fMet-tRNA to 70S ribosomes was inhibited by both streptomycin and by kasugamycin. [1].
In vivo: Five groups, each consisting of five guinea pigs, were infected with Shibaura strain; two groups were treated by injection with kasugamycin. All animals treated with 1 mcg/g were killed showing an average survival period of 7.4 days, which was close to the average survival period of 6.2 days in the control group; while all animals treated with 5 mcg/g survived. The other two groups were treated with kasugamycin from the icteric stage to the 10th day after infection. Two animals of the 5 mcg/g group survived, showing no leptospira in the kidney; the other three died in an average of 7.7 days. Three animals of the 10 mcg/g group survived; while the other two animals died in 6.5 days on an average . The total amounts of kasugamycin administered to the infected guinea pigs from the febrile stage were 10.8 mg (the 1 mcg/g group) and 54.0 mg (the 5 mcg/g group) [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Okuyama, A. ,Machiyama, N.,Kinoshita, T., et al. Inhibition by kasugamycin of initiation complex formation on 30S ribosomes. Biochemical and Biophysical Research Communications 43(1), 196-199 (1971).
[2] Kitaoka M, Mori M, Arimitsu Y. In vitro and in vivo effects of kasugamycin on Leptospira icterohaemorrhagiae. Jpn J Med Sci Biol. 1975 Oct-Dec;28(5-6):285-90.
Cas No. | 19408-46-9 | SDF | |
别名 | 春雷霉素盐酸盐; Ksg hydrochloride | ||
化学名 | 3-O-[2-amino-4-[(carboxyiminomethyl)amino]-2,3,4,6-tetradeoxy-α-D-arabino-hexopyranosyl]-D-chiro-inositol, monohydrochloride | ||
Canonical SMILES | O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2([H])O[C@H](C)[C@@H](NC(C(O)=O)=N)C[C@@H]2N)[C@@H]1O.Cl | ||
分子式 | C14H25N3O9 • HCl | 分子量 | 415.8 |
溶解度 | ≥ 41.6mg/mL in Water with gentle warming | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.405 mL | 12.025 mL | 24.05 mL |
5 mM | 0.481 mL | 2.405 mL | 4.81 mL |
10 mM | 0.2405 mL | 1.2025 mL | 2.405 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >90.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet